Q-omics provides the consensus-scored ARGFX profile across patient tissues and cancer cell-line models. ARGFX expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ARGFX is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, ARGFX RNA expression shows 6,729 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, THCA, and STAD as cancer lineages where ARGFX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARGFX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARGFX survival associations across molecular data types. ARGFX RNA expression shows survival associations in the most cancer types (14), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARGFX RNA expression–survival associations across cancer types. High ARGFX expression shows unfavorable associations in KICH, DLBC, BLCA, SKCM and THYM, but favorable associations in LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for ARGFX RNA expression.
This table summarizes ARGFX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ARGFX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARGFX shows lower tumor expression in THCA and higher tumor expression in LUAD. The THCA box plot shows higher ARGFX RNA expression in normal versus tumor tissue (log2 FC = −0.017, t-test p = .025).
This table shows molecular features associated with ARGFX in patient tissues and cancer cell lines. In patient samples, ARGFX shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ARGFX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and STOMACH.
